Clozaril (Clozapine) associated neutropenia and agranulocytosis

Atkin, K; Kendall, Frank M.; Arellano, Félix; O'Sullivan, D; Krupp, P.

doi:10.1016/0920-9964(96)85421-1

Schizophrenia Research

1996

DOI: 10.1016/0920-9964(96)85421-1

|View full text |Cite

Clozaril (Clozapine) associated neutropenia and agranulocytosis

K Atkin¹,

Frank M. Kendall²,

Félix Arellano³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1996

1997

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

New Dimensions in the Pharmacologic Treatment of Schizophrenia and Related Psychoses

Buckley

1997

The Journal of Clinical Pharma

View full text Add to dashboard Cite

During the past 5 years unprecedented advances have taken place in the psychopharmacology of schizophrenia and related psychoses. Clozapine and risperidone, two prototypic novel antipsychotic drugs, have had a significant impact on the treatment of psychotic disorders. Additionally, they have ushered in another generation of antipsychotic drugs with complex pharmacologic profiles, potentially enhanced efficacy, and more benign side-effect profiles than previously associated with conventional antipsychotic medications. This review highlights these developments, implications for the management of psychotic disorders, and the use of novel antipsychotic drugs in specific clinical subgroups.

show abstract

New Dimensions in the Pharmacologic Treatment of Schizophrenia and Related Psychoses

Buckley

1997

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

Clozapine and Risperidone: Refining and Extending Their Use

Buckley

Schulz

1996

Harvard Review of Psychiatry

View full text Add to dashboard Cite

The recent advent of atypical antipsychotic medications has provided new clinical options and set higher expectations for the treatment of schizophrenia and other psychoses. Two such drugs, clozapine and risperidone, are currently employed in the United States. Researchers continue to fine-tune treatment with these agents and to seek possible new uses for them. For clozapine, refinements in use (optimal duration of trial, optimal dose, use of drug plasma level to optimize efficacy) are described, along with side effects and the specificity (or lack thereof) of the drug's action upon primary negative symptoms. Also discussed is use of clozapine in new subgroups of patients--for example, those with first-episode schizophrenia, polydipsia syndrome, or a dual diagnosis. For risperidone, use in patients with first-episode schizophrenia, affective disorders, autism, and other disorders in described. Cost-benefit considerations are presented for both drugs. The psychosocial needs of patients taking these medications and the potential for synergy between novel antipsychotics and modern psychosocial therapies are also discussed.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Clozaril (Clozapine) associated neutropenia and agranulocytosis

Cited by 2 publications

References 0 publications

New Dimensions in the Pharmacologic Treatment of Schizophrenia and Related Psychoses

New Dimensions in the Pharmacologic Treatment of Schizophrenia and Related Psychoses

Clozapine and Risperidone: Refining and Extending Their Use

Contact Info

Product

Resources

About